Dicerna Pharmaceuticals
Our Company
Management Team
Board of Directors
Partnering
Intellectual Property
Our Technology
The Promise of RNAi
DsiRNA: Dicerna’s Therapy Platforms
Our GalXC
TM
Technology Platform: Enhancing the Utility of DsiRNA-EX Molecules
Glossary of Key Terms
Pipeline
Primary Hyperoxaluria
Novel Investigational Drug for PH: DCR-PHXC
PHYOX: Phase 1 Clinical Development Program
PHYOS: Primary HYperoxaluria Observational Study
Patients
Patient Resources
Investors & Media
Press Releases
Press Coverage
Events & Presentations
Corporate Governance
Management
Board of Directors
Committee Composition
Contact the Board
Financials & Filings
SEC Filings
Stock Information
Historic Stock Lookup
Investment Calculator
Analyst Coverage
Investor FAQs
Contact
Our Company
Management Team
Board of Directors
Partnering
Intellectual Property
Our Technology
The Promise of RNAi
DsiRNA: Dicerna’s Therapy Platforms
Our GalXC
TM
Technology Platform: Enhancing the Utility of DsiRNA-EX Molecules
Glossary of Key Terms
Pipeline
Primary Hyperoxaluria
Novel Investigational Drug for PH: DCR-PHXC
PHYOX: Phase 1 Clinical Development Program
PHYOS: Primary HYperoxaluria Observational Study
Patients
Patient Resources
Investors & Media
Press Releases
Press Coverage
Events & Presentations
Corporate Governance
Management
Board of Directors
Committee Composition
Contact the Board
Financials & Filings
SEC Filings
Stock Information
Historic Stock Lookup
Investment Calculator
Analyst Coverage
Investor FAQs
Contact
Search for:
News
Careers
Contact
Home
/
News
News
News
Sign up for Email Alerts
Dicerna Pharmaceuticals
Dicerna Pharmaceuticals